New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Sanofi

SNY

Healthcare Drug Manufacturers General

Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.

Revenue
+13.9%
EPS
+8.21%
Free cash flow
+99.6%
Total debt
−11.2%

Quarter to September 2026, against a year earlier

46.59 0.53 +1.15%
Market cap
$111.3B
P/E
22.8×
Fwd P/E FY26e
—
Dividend yield
5.25%
F-score
7/9
ROIC
7.05%
Net debt / EBITDA
0.8×
Payout ratio
1.2×

Where the cash went Q3 FY2026, quarter to Sep 30, 2026

Free cash flow was $4.4B, and none of it went on dividends or buybacks. Cash fell by $426.6M. Lines the picture does not name came to −$4.8B. What is a cash flow statement?

Free cash flow
$4.4B 100.0% of operating cash flow
Returned to shareholders
$0.00 0.00% of free cash flow
Debt, net
$0.00 borrowed
Change in cash
−$426.6M over the period
Where the cash went, in billions of dollars
Operating cash flow4.4
Free cash flow4.4
Other−4.8
Change in cash−0.4

Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Operating Cash Flow
4,401.20 5,398.42 — 12,162.55

+8 more quarters

Investing cash flow
(591.77) (3,073.02) — (2,768.54)
Financing cash flow
(4,234.68) (3,874.12) — (9,285.40)
Ending Cash
(516.28) 7,383.15 — 8,663.13

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 5, 2026